Aerivio Spiromax Evropska unija - slovenščina - EMA (European Medicines Agency)

aerivio spiromax

teva b.v. - salmeterol xinafoate, fluticasone propionat - pulmonary disease, chronic obstructive; asthma - zdravila za obstruktivne pljučne bolezni, - zdravilo aerivio spiromax je indicirano za uporabo pri odraslih, starejših od 18 let in starejših. asthmaaerivio spiromax je določen za redno zdravljenje bolnikov s hudo astmo, kjer je uporaba kombinacije izdelka (pri vdihavanju kortikosteroidi in dolgo delujoči agonist β2) je ustrezno:bolniki, ki ni ustrezno nadzorovana na nižji moči kortikosteroidi kombinacija izdelek orpatients že pod nadzorom na visoki odmerek pri vdihavanju kortikosteroidi in dolgo delujoči agonist β2. kronična obstruktivna pljučna bolezen (kopb)aerivio spiromax je primerna za simptomatsko zdravljenje bolnikov s kopb s fev1.

Airexar Spiromax Evropska unija - slovenščina - EMA (European Medicines Agency)

airexar spiromax

teva b.v. - salmeterol, fluticasone propionat - pulmonary disease, chronic obstructive; asthma - zdravila za obstruktivne pljučne bolezni, - airexar spiromax je indicirano za uporabo pri odraslih, starih 18 let in več, samo. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. kronična obstruktivna pljučna bolezen (kopb)airexar spiromax je primerna za simptomatsko zdravljenje bolnikov s kopb s fev1.

BroPair Spiromax Evropska unija - slovenščina - EMA (European Medicines Agency)

bropair spiromax

teva b.v. - salmeterol xinafoate, fluticasone propionat - astma - zdravila za obstruktivne pljučne bolezni, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Seffalair Spiromax Evropska unija - slovenščina - EMA (European Medicines Agency)

seffalair spiromax

teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - zdravila za obstruktivne pljučne bolezni, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

BiResp Spiromax Evropska unija - slovenščina - EMA (European Medicines Agency)

biresp spiromax

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - zdravila za obstruktivne pljučne bolezni, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).